

Health Care: Drugs
Kendle International Inc. (KNDL: NASDAQ)
$15.24 0.00 | 0.03%
07/11/11 - 04:00 PM ET
197.40K / 356.60K
Vol / Avg. Vol:
15.24 / 15.23
Open / Prev. Close:
15.22 - 15.25
Today's Range:
Portfolios with KNDL
Latest KNDL Headlines from TheStreet
More Financial News for KNDL
Press Releases for KNDL
- Kendle International Inc. Announces Expiration Of Tender Offer And Consent Solicitation For Convertible Notes - PR Newswire 07.12.11 | 04:07 pm
- Kendle International Inc. Announces Extension Of Expiration Time Of Tender Offer And Consent Solicitation For Convertible Notes - PR Newswire 07.06.11 | 05:07 pm
- Kendle International Inc. Increases Consideration Amount For Tender Offer And Consent Solicitation For Convertible Notes - PR Newswire 06.17.11 | 08:06 am
- Kendle Experts To Address Key Industry Issues At Drug Information Association 47th Annual Meeting - PR Newswire 06.16.11 | 12:06 pm
- Kendle Appoints Pierre Geoffroy, MD, CM, MSc, FCFP Vice President, Early Stage - PR Newswire 06.07.11 | 09:06 am
- Kendle International Inc. Commences Tender Offer And Consent Solicitation For Convertible Notes - PR Newswire 06.06.11 | 09:06 am
- Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology - PR Newswire 06.02.11 | 09:06 am
- Bull & Lifshitz, LLP Announces Investigation Of The Acquisition Of Kendle International Inc. - Business Wire 05.19.11 | 04:05 pm
- The Law Office Of Joseph Klein Is Investigating Possible Breaches Of Fiduciary Duty By The Board Of Kendle International, Inc. In Connection With The Sale Of The Company To INC Research, LLC -- KNDL - Business Wire 05.17.11 | 07:05 pm
- Kendle Rated A "Top CRO To Work With" For Fifth Consecutive Year - PR Newswire 05.12.11 | 09:05 am
See All Press Releases
Partner Headlines for KNDL